美国显影剂市场规模、份额和趋势分析报告：按模式、类型、应用和细分市场预测，2023-2030 年

美国显影剂市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年美国显影剂市场规模将达33.6亿美元，2023年至2030年复合年增长率为4.1%。

慢性病负担的增加正在创造对诊断影像的需求，从而推动市场成长。 MRI 等影像检查已成为大多数疾病诊断的关键，影像技术在医疗保健领域的大规模渗透正在推动美国市场对显影剂的需求。癌症和糖尿病等慢性疾病正在迅速成为主要的公共卫生问题，并且是美国各地的主要原因之一，因此需要早期诊断工具和有效的治疗方案。我就是。

因此，复杂合併症和长期疾病的盛行率不断增加是影像检查和显影剂的主要驱动因素之一，促进了市场成长。由于就诊患者减少，COVID-19 疫情对市场产生了负面影响。在许多放射科，诊断影像病例数迅速减少。然而，美国许多州已经开始重新开放经济。然而，显影剂使用率要达到疫情前的水平还需要一段时间。此外，由于COVID-19疫苗的发布和监管的放鬆，原料进出口已恢復。预计这将推动预测期内的市场成长。

美国显影剂市场报告亮点

• MRI 等影像检查对于大多数疾病的诊断至关重要，影像技术在医疗保健领域的大规模普及正在推动美国市场对显影剂的需求。
• 碘显影剂由于与其他造影剂相比具有优越的渗透性和低毒性，在市场显影剂占据主导地位，到 2022 年将占据最大份额，超过 60%。
• X光/CT细分市场占据主导地位，2022年占最大份额，约65%。 X 光/CT 模式的广泛接受度和成本效益正在推动该模式采用显影剂。
• 对诊断影像的需求不断增长，促使显影剂製造商进行广泛的研究和开发工作，以将新产品推向市场并获得新适应症的核准。
• 例如，2021 年，Bracco 的 20 瓶装 Lumason（一种超音波显影剂）获得美国FDA核准。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章美国显影剂市场变数、趋势、范围

• 市场体系展望
  • 母市场展望
  • 相关/附随市场展望
• 普及和成长前景图
• 市场动态
  • 市场驱动因素分析
  • 市场抑制因素分析
• 美国显影剂市场分析工具
  • 产业分析-波特五力分析
  • PESTEL分析

第四章美国显影剂：类型估计与趋势分析

• 美国显影剂市场，按类型分類的要点
• 美国显影剂市场：2022 年和 2030 年趋势与市场占有率分析
• 微气泡显影剂
• 钆基显影剂
• 碘显影剂
• 钡显影剂

第五章美国显影剂：模态估计与趋势分析

• 美国显影剂市场，按模式分類的要点
• 美国显影剂市场：2022 年和 2030 年趋势与市场占有率分析
• 超音波
• 磁振造影(MRI)
• X 光/电脑断层扫描（电脑断层扫描）

第六章美国显影剂：使用估计和趋势分析

• 美国显影剂市场，按应用分類的要点
• 美国显影剂市场：2022 年和 2030 年趋势与市场占有率分析
• 心血管
• 神经系统疾病
• 胃肠道疾病
• 癌症
• 肾臟疾病
• 肌肉骨骼疾病
• 其他的

第七章竞争形势

• 主要市场参与企业的最新趋势和影响分析
• 公司/竞争分类
  • Bayer AG
  • GE Healthcare
  • Guerbet
  • Lantheus Medical Imaging, Inc
  • Bracco Diagnostic Inc
  • Trivitron Healthcare
  • Nano Therapeutics Pvt Ltd.
  • IMAX Diagnostic Imaging
  • CMC Contrast AB (ASCELIA PHARMA AB)

U.S. Contrast Media Market Growth & Trends:

The U.S. contrast media market size is expected to reach USD 3.36 billion by 2030, registering a CAGR of 4.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing burden of chronic diseases is creating a demand for diagnostic imaging procedures, which, in turn, is driving the market growth. Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market. Chronic diseases, such as cancer and diabetes, are rapidly becoming a major public health concern and are among the leading causes of death across the U.S., resulting in the need for early diagnostic tools and effective treatment options.

Hence, the increasing prevalence of complex comorbidities and long-term diseases is one of the major drivers of imaging tests and contrast agents; thus, contributing to the market growth. The COVID-19 outbreak had a negative impact on the market due to decreased patient visits to hospitals. Many radiology departments experienced a rapid decline in imaging case volume. However, many states in the U.S. have begun to reopen their economies; however, it will take time for the utilization rate of contrast media to reach pre-pandemic levels. In addition, with the launch of COVID-19 vaccines and ease in restrictions, the import and export of raw materials have resumed. This, in turn, therefore, is expected to boost the market growth over the forecast period.

U.S. Contrast Media Market Report Highlights:

• Imaging tests, such as MRI, have become an integral part of the diagnosis for most diseases, and large-scale penetration of imaging technology in healthcare has increased the demand for contrast media in the U.S. market
• The iodinated contrast media dominated the market and held the largest market share of over 60% in 2022 on account of excellent radio-opacity and low toxicity of iodinated contrast media than other agents
• The X-ray/CT segment dominated the market and held the largest market share of around 65% in 2022. Wide acceptance and cost-efficiency of X-ray/CT modality boost the adoption of contrast agents for this modality
• The rising demand for imaging procedures has resulted in extensive R&D activities by contrast media manufacturers to launch novel products in the market and to get approved for new indications
• For instance, in 2021, Bracco got the U.S. FDA approval for 20-vial pack configuration of Lumason, which is an ultrasound contrast media agent

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Modality
  • 1.1.3. Application
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Modality outlook
  • 2.2.3. Application outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Contrast Media Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. U.S. Contrast Media Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. U.S. Contrast Media: Type Estimates & Trend Analysis

• 4.1. U.S. Contrast Media Market, By Type Key Takeaways
• 4.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Microbubble Contrast Media
  • 4.3.1. Microbubble contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Gadolinium-based Contrast Media
  • 4.4.1. Gadolinium-based contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Iodinated Contrast Media
  • 4.5.1. Iodinated contrast media market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Barium-based Contrast Media
  • 4.6.1. Barium-based contrast media market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Contrast Media: Modality Estimates & Trend Analysis

• 5.1. U.S. Contrast Media Market, By Modality Key Takeaways
• 5.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Ultrasound
  • 5.3.1. Ultrasound market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Magnetic Resonance Imaging (MRI)
  • 5.4.1. Magnetic resonance (MRI) imaging market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. X-RAY/Computed Tomography (CT Scan)
  • 5.5.1. X-RAY/computed tomography (CT Scan) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Contrast Media: Application Estimates & Trend Analysis

• 6.1. U.S. Contrast Media Market, By Application Key Takeaways
• 6.2. U.S. Contrast Media Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Cardiovascular
  • 6.3.1. Cardiovascular market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Neurological Disorders
  • 6.4.1. Neurological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Gastrointestinal Disorders
  • 6.5.1. Gastrointestinal disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Cancer
  • 6.6.1. Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Nephrological Disorders
  • 6.7.1. Nephrological disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Musculoskeletal Disorders
  • 6.8.1. Musculoskeletal disorders market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Others
  • 6.9.1. Others market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
  • 7.2.1. Bayer AG
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. GE Healthcare
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Guerbet
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Lantheus Medical Imaging, Inc
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Bracco Diagnostic Inc
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Trivitron Healthcare
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Nano Therapeutics Pvt Ltd.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. IMAX Diagnostic Imaging
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. CMC Contrast AB (ASCELIA PHARMA AB)
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviation
• Table 2 U.S. U.S. contrast media market, by type, 2018 - 2030 (USD Million)
• Table 3 U.S. U.S. contrast media market, by modality, 2018 - 2030 (USD Million)
• Table 4 U.S. U.S. contrast media market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. contrast media: Market outlook
• Fig. 9 U.S. contrast media: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 U.S. contrast media market driver impact
• Fig. 15 U.S. contrast media market restraint impact
• Fig. 16 U.S. contrast media market strategic initiatives analysis
• Fig. 17 U.S. contrast media market: Type movement analysis
• Fig. 18 U.S. contrast media market: Type outlook and key takeaways
• Fig. 19 Microbubble Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Gadolinium-based Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Iodinated Contrast Media market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Barium-based Contrast media market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 U.S. contrast media market: Modality movement analysis
• Fig. 25 U.S. contrast media market: Modality outlook and key takeaways
• Fig. 26 Ultrasound market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Magnetic resonance imaging (MRI) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 X-ray/computed tomography (CT scan) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 U.S. contrast media market: Application movement analysis
• Fig. 30 U.S. contrast media market: Application outlook and key takeaways
• Fig. 31 Cardiovascular conditions market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Neurological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Gastrointestinal disorders management market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Nephrological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Musculoskeletal disorders market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Others market estimates and forecasts, 2018 - 2030 (USD Million)